Black Diamond Therapeutics, Inc.
BDTX$141M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaCAMBRIDGE24 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
BDTX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
silevertinib (BDTX-1535) monotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply